Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to SADBE in HSV-1
NCT03661541Phase 1Completed
- Sponsor
- Squarex Pharma
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of squaric acid dibutyl ester in herpes labialis (3 arms), sponsored by Squarex Pharma. Primary endpoints: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs at 8 weeks and Immune Monitoring - PBMC Proliferation at 8 weeks. Started Mar 2017; status: completed.
02
Drugs
squaric acid dibutyl ester
03
Conditions
herpes labialis
Beyond the preview
Go deeper on NCT03661541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661541.